Kurowski Michael, Walli Ravi K, Breske Antje, Kruse Guido, Stocker Hartmut, Banik Norbert, Richter Heinz, Mazur Dago
Therapia GmbH, Berlin, Germany.
AIDS. 2007 Jun 19;21(10):1368-70. doi: 10.1097/QAD.0b013e32810c8ce2.
The effect of tenofovir disoproxil fumarate (TDF) in combination with two boosted fosamprenavir regimens on amprenavir pharmacokinetic parameters was assessed in this prospective phase I crossover study with 30 healthy volunteers. The co-administration of TDF 300 mg once a day with fosamprenavir/ritonavir 1400/200 mg or 1400/100 mg once a day has no effect on the pharmacokinetics of amprenavir and results in non-significant increases of ritonavir pharmacokinetic parameters, suggesting that no dose modification is necessary when combining fosamprenavir/ritonavir with TDF.
在这项有30名健康志愿者参与的前瞻性I期交叉研究中，评估了替诺福韦酯（TDF）与两种增强型福沙那韦方案联合使用对安普那韦药代动力学参数的影响。每天一次服用300 mg TDF与每天一次服用1400/200 mg或1400/100 mg福沙那韦/利托那韦共同给药，对安普那韦的药代动力学没有影响，并且导致利托那韦药代动力学参数无显著增加，这表明福沙那韦/利托那韦与TDF联合使用时无需调整剂量。
